May Newsletter

Posted:05/6/10

Annual Conference Dates and Deadlines

Power is Teal Conference

Saturday, July 10 – Tuesday, July 13
Washington, DC
www.ovariancancer.org/conference/2010

The Ovarian Cancer National Alliance’s Annual Conference is the largest ovarian cancer specific conference that brings together researchers, clinicians, survivors and caregivers to learn about the latest developments in diagnosis, treatment and quality of life for women with ovarian cancer.

Each year, we commit to helping as many survivors and caregivers as possible. This year, we are offering scholarships of up to $500 to attend the Power is Teal Conference. We want YOU to be there! The application process is now open through Friday, May 14, 2010. All applicants will be notified by Monday, May 31, 2010 with the results. To receive an application, click here.

Important Conference Deadlines

Friday, May 14, 2010 – Last day to submit scholarship applications
Monday, May 31, 2010 – Last day to submit award nominations
Monday, May 31, 2010 – Early Registration Ends
Friday, June 4, 2010 – Last day to register for Advocacy Day
Friday, June 18, 2010 – Last day to reserve a hotel room at the  Conference rate
Wednesday, July 7, 2010 – Last day to register online

For more information about this year’s Power is Teal Conference, visit www.ovariancancer.org/conference/2010.

From the Policy Department

Important Update on Medicare Coverage

Many cancer treatments are off-label, meaning that there is evidence supporting their use but the drug has not been approved by the Food and Drug Administration (FDA) for that specific treatment.  Medicare coverage of off-label drugs is governed by a law that requires coverage to be evidence based and on scientific guidelines called compendia.  Only one compendia, assembled by the National Comprehensive Cancer Network (NCCN), is publicly available.

The drug bevacizumab (known as Avastin), is commonly used off-label to treat ovarian cancer, although it is not approved by the FDA for ovarian cancer.  Recently, many Medicare patients with ovarian cancer have had problems getting coverage for use of Avastin off-label.  The NCCN compendia includes using Avastin for ovarian cancer.

The Ovarian Cancer National Alliance believes that denials of coverage for off label use of drugs that are on the compendia violates the law.  Numerous Members of Congress have gone on record decrying these denials, and recently, the Ovarian Cancer National Alliance met with representatives of the Center for Medicare and Medicaid Services regarding this issue.  We will keep you updated on progress, but if you have trouble with Medicare reimbursement, please contact the Ovarian Cancer National Alliance at ocna@ovariancancer.org or (202)331-1332.

Appropriations Update:

Department of Defense Ovarian Cancer Research Program

In last month’s newsletter, we asked you to contact your Senators and request that they sign a letter in support of appropriating $30 million to the Department of Defense Ovarian Cancer Research Program (DoD OCRP) in FY 2011.  Thanks to your calls and emails, 25 Senators signed the letter. To see the final letter and a list of signers, please click here.

Action Alert

Please thank your Senators if they signed on or politely express your disappointment if they did not sign on. Click here to send an email.

What’s New?

Our Power is Teal t-shirts

The official t-shirt for the EIF Revlon Run/Walk For Women and the 2010 Power is Teal Conference.

Upcoming Events

Mothers We Love Campaign

May 2010

www.ovariancancer.org/mothers-we-love

13th Annual Ovarian Cancer National Alliance Power is Teal Conference

July 10-13, 2010

Washington, DC

Registration is Now Open!!

www.ovariancancer.org/conference/2010

Wear TEAL Day!

Friday, September 3, 2010

*first Friday in September